Leaders seeking to commercialize more research often cite a need for more early-stage funding. The Nexus Fund is focused on biomedical startups that were born at institutions in Maryland.

Camden Partners announced the final close of its venture capital fund that is seeking to invest in startups that originated at Maryland’s research institutions.

The Camden Partners Nexus Fund is focusing on supporting early stage startups commercializing biomedical technology coming from research institutions like Johns Hopkins and the University of Maryland, according to a press release.

A lack of early stage funding is frequently cited as a barrier for startups looking bring research out of the lab and into the market, so the appearance of a Baltimore-based fund is notable for the tech-transfer community. For Inner Harbor–based Camden Partners, it marks the first foray into an early stage venture capital fund for a firm that normally focuses on later-stage deals.

Click here to read the rest of the story via Technical.ly Baltimore.